Literature DB >> 20414200

Adaptive trials receive boost.

Dan Jones.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20414200     DOI： 10.1038/nrd3174

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 2.  Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.

Authors:  Mario R Ehlers; Gerald T Nepom
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Reengineering translational science: the time is right.

Authors:  Francis S Collins
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

4.  Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  J Pharm Bioallied Sci       Date:  2010-10

5.  Patient-centeredness in the design of clinical trials.

Authors:  C Daniel Mullins; Joseph Vandigo; Zhiyuan Zheng; Paul Wicks
Journal:  Value Health       Date:  2014-05-05       Impact factor: 5.725

Review 6.  Strategies for clinical trials in type 1 diabetes.

Authors:  Mario R Ehlers
Journal:  J Autoimmun       Date:  2016-04-05       Impact factor: 7.094

7.  Adaptive design clinical trials: Methodology, challenges and prospect.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

8.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

Authors:  Dai Horiuchi; Leonard Kusdra; Noelle E Huskey; Sanjay Chandriani; Marc E Lenburg; Ana Maria Gonzalez-Angulo; Katelyn J Creasman; Alexey V Bazarov; James W Smyth; Sarah E Davis; Paul Yaswen; Gordon B Mills; Laura J Esserman; Andrei Goga
Journal:  J Exp Med       Date:  2012-03-19       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.